Kyverna Therapeutics, Inc. - Common Stock (KYTX)
2.6300
+0.0400 (1.54%)
Kyverna Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and related conditions
The company specializes in harnessing the power of engineered immune cells to create transformative treatment options. By utilizing advanced genetic engineering techniques, Kyverna aims to target and modify the immune system's response, thereby addressing the underlying causes of autoimmune disorders. Through its research and development initiatives, the company strives to deliver novel, effective solutions that improve patient outcomes and enhance quality of life for those affected by these challenging diseases.
Previous Close | 2.590 |
---|---|
Open | 2.520 |
Bid | 2.510 |
Ask | 2.790 |
Day's Range | 2.501 - 2.710 |
52 Week Range | 2.501 - 30.60 |
Volume | 269,833 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 309,858 |
News & Press Releases

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQKYTX) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company’s February 2024 initial public offering (the “IPO” or the “Offering”).
By The Law Offices of Frank R. Cruz · Via Business Wire · February 5, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 4, 2025
RADNOR, PA - February 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · February 4, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 4, 2025

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kyverna Therapeutics, Inc. (NASDAQKYTX), Sun Communities NYSE: SUINYSESUI)(NASDAQ: BOOMNASDAQBOOM, and Marqeta, Inc. (NASDAQ:MQNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · February 3, 2025

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NasdaqGS: KYTX), if they purchased the Company’s shares pursuant and/or traceable to the Company’s registration statement issued in connection with its February 2024 initial public offering (“IPO”). This action is pending in the United States District Court for the Northern District of California.
By Kahn Swick & Foti, LLC · Via Business Wire · February 3, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 3, 2025
RADNOR, PA - February 3, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · February 3, 2025

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · February 3, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 2, 2025
RADNOR, PA - February 2, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · February 2, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 2, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 1, 2025
RADNOR, PA - February 1, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · February 1, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 30, 2025
RADNOR, PA - January 30, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 30, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 29, 2025
RADNOR, PA - January 29, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 29, 2025

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kyverna Therapeutics, Inc. (NASDAQKYTX), Five9, Inc. NASDAQ: FIVNNASDAQFIVN)(NASDAQ: BOOMNASDAQBOOM, and Marqeta, Inc. (NASDAQ:MQNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 28, 2025
RADNOR, PA - January 28, 2025 (NEWMEDIAWIRE) -The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 28, 2025

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · January 27, 2025

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · January 27, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 26, 2025
RADNOR, PA - January 26, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 26, 2025